Speaking at the Danish Shareholders Association's Investordagen event,
$NVO CEO Mike Doustdar discussed the company's long-term growth ambitions and its efforts to regain investor confidence.
At its Capital Markets Day in September, Novo Nordisk announced a target of delivering sales growth in line with the pharmaceutical industry through 2030, corresponding to mid-single-digit annual growth.
However, Mike Doustdar made it clear that the company is aiming higher.
He explained that management's responsibility is to establish realistic targets it believes it can achieve and then work hard to exceed them.
The comments come after a challenging period for Novo Nordisk, marked by increasing competition in obesity treatments, disappointing clinical trial results, and significant management changes.
In response, the company has shifted toward a more consumer-focused commercial strategy in 2026.
This includes lower prices, partly through agreements with the Trump administration, combined with an emphasis on reaching significantly more patients.
The strategy is based on generating higher sales volumes to compensate for lower prices.
Novo Nordisk has also gradually improved its 2026 outlook throughout the year.
What initially looked like a year of declining sales and earnings has developed into expectations of approximately flat performance.
Mike Doustdar also emphasized that Novo Nordisk is determined to outperform its competitors.
He made it clear that everyone at the company, including himself, wants to beat the competition and is actively looking for ways to achieve that.
For investors, the interesting takeaway is that Novo Nordisk's mid-single-digit growth target through 2030 should not necessarily be interpreted as management's ultimate ambition.
Mike Doustdar appears determined to rebuild confidence by setting achievable expectations and then delivering results above them.
Whether Novo Nordisk can achieve that will depend on its ability to grow patient volumes, compete effectively with
$LLY , and successfully launch new treatments over the coming years.